Overview

Anlotinib and Irinotecan for Ewing Sarcoma

Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Camptothecin
Irinotecan